Losing The War? Novo's Prandin Patent Ruled Invalid After Generics Cleverly Blocked At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Use of repaglinide in combination with metformin is obvious, judge rules in finding the method of use patent invalid; the ruling may clear the way for generic competition, but Caraco still faces manufacturing hurdle.
You may also be interested in...
Patent Use Codes For Brands Can Be Challenged By Generics, Supreme Court Rules
The high court says the Hatch-Waxman Act did not intend for one patented use of a drug to prevent the marketing of a generic for unpatented uses; Justice Sotomayor criticizes FDA for not providing clearer direction to brand manufacturers about what to include in their use codes.
Patent Use Codes: Will Supreme Court Curb Carve-outs Or Spawn Suits?
The high court hears oral arguments in a case that could limit the ability of generics to carve out still-patented uses from their labeling to get prompt ANDA approval. Brand manufacturers argue that allowing such challenges will invite a flood of lawsuits. Caraco v. Novo revolves around a patent use code for the diabetes drug Prandin.
Supreme Court To Consider Patent Use Codes, But At Best Can Give Generic Firms A Hunting License
The Supreme Court will address whether an ANDA sponsor can challenge a brand name company's alteration of a drug's patent use code to block generic competition.